Core Erythropoietin Receptor Signals for Late Erythroblast Development
Overview
Authors
Affiliations
Critical signals for erythroblast formation are transduced by activated, tyrosine-phosphorylated erythropoietin receptor (EpoR) complexes. Nonetheless, steady-state erythropoiesis is supported effectively by EpoR alleles that are deficient in cytoplasmic phosphotyrosine sites. To better define core EpoR action mechanisms, signaling capacities of minimal PY-null (EpoR-HM) and PY343-retaining (EpoR-H) alleles were analyzed for the first time in bone marrow-derived erythroblasts. Jak2 activation via each allele was comparable. Stat5 (and several Stat5-response genes) were induced via EpoR-H but not via EpoR-HM. Stat1 and Stat3 activation was nominal for all EpoR forms. For both EpoR-HM and EpoR-H, Akt and p70S6-kinase activation was decreased multifold, and JNK activation was minimal. ERKs, however, were hyperactivated uniquely via EpoR-HM. In vivo, Epo expression in EpoR-HM mice was elevated, while Epo-induced reticulocyte production was diminished. In vitro, EpoR-HM erythroblast maturation also was attenuated (based on DNA content, forward-angle light scatter, and hemoglobinization). These EpoR-HM-specific defects were corrected not only upon PY343 site restoration in EpoR-H, but also upon MEK1,2 inhibition. Core EpoR PY site-independent signals for erythroblast formation therefore appear to be Stat5, Stat1, Stat3, p70S6-kinase, and JNK independent, but ERK dependent. Wild-type signaling capacities, however, depend further upon signals provided via an EpoR/PY343/Stat5 axis.
An W, Feola M, Levy M, Aluri S, Ruiz-Martinez M, Sridharan A Elife. 2023; 12.
PMID: 38153418 PMC: 10754500. DOI: 10.7554/eLife.83103.
Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review.
Hamza E, Metzinger L, Metzinger-Le Meuth V Cells. 2020; 9(9).
PMID: 32899941 PMC: 7565991. DOI: 10.3390/cells9092039.
Samson F, He W, Sripathi S, Patrick A, Madu J, Chung H ACS Omega. 2020; 5(33):21113-21126.
PMID: 32875248 PMC: 7450639. DOI: 10.1021/acsomega.0c02763.
Di Giandomenico S, Kermani P, Molle N, Yabut M, Abu-Zeinah G, Stephens T Blood. 2020; 136(9):1044-1054.
PMID: 32548608 PMC: 7453150. DOI: 10.1182/blood.2019003276.
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).
Parmentier J, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M BMC Rheumatol. 2019; 2:23.
PMID: 30886973 PMC: 6390583. DOI: 10.1186/s41927-018-0031-x.